Last edition
News about "Chemistry42"
Insilico Medicine to Present ISM6331 Phase 1 Data at ESMO 2026
Insilico Medicine will present phase 1 data for Artificial Intelligence (AI)-designed pan-TEAD inhibitor ISM6331 at ESMO 2026 in mesothelioma and advanced solid tumors.
Chemistry42 | 28/07/2026 | By News Bureau
TaiGen Biotechnology doses first participant in Phase I trial of ISM4808, an AI-designed oral therapy from Insilico Medicine for chronic kidney disease-related anemia.
Chemistry42 | 09/03/2026 | By News Bureau | 243
Insilico Medicine and Hygtia Therapeutics have entered a co-development deal for ISM8969, an AI-designed, brain-penetrant NLRP3 inhibitor, with milestone payments of up to USD 66 million.
Chemistry42 | 21/01/2026 | By News Bureau | 278
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy